Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class…

PONTE VEDRA, Fla., Dec. 11, 2025 -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced the acquisition...

Home
About
Team
Portfolio
Ventures
Specialized Fund Management
Translational Medicine
- About
- Wake Forest Technology Development Program

logo_white

veteran_logo_white

Home
About
Team

Portfolio
News & Events
Contact

Ventures
Specialized Funds
Translational Medicine

NVCA

bio

nc-biotech

© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.

© 2018 Pappas Capital, LLC. ALL RIGHTS RESERVED.